Syntaxin is a biopharmaceutical company that discovers and develops a new class of biopharmaceuticals that treat disease through selective inhibition of cell secretory processes.  These are potent drugs that can be administered locally or systemically with duration of action from weeks to months from a single dose, and have potential in the treatment of diseases involving aberrant cell secretion such as Endocrine disorders, CNS/PNS disorders, Inflammatory diseases, Immunomodulation and Oncology.  Current clinical and preclinical programmes address Pain, Acromegaly, other Endocrine disorders, and Inflammatory diseases.  The company has a portfolio of over 40 granted patents covering platform and products.